5ETV image
Deposition Date 2015-11-18
Release Date 2016-05-04
Last Version Date 2024-11-20
Entry Detail
PDB ID:
5ETV
Title:
S. aureus 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with AMPCPP and inhibitor at 1.72 angstrom resolution
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.72 Å
R-Value Free:
0.20
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 61
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase
Chain IDs:A
Chain Length:161
Number of Molecules:1
Biological Source:Staphylococcus aureus
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CSO A CYS modified residue
Primary Citation
Structural Basis for the Selective Binding of Inhibitors to 6-Hydroxymethyl-7,8-dihydropterin Pyrophosphokinase from Staphylococcus aureus and Escherichia coli.
J.Med.Chem. 59 5248 5263 (2016)
PMID: 27094768 DOI: 10.1021/acs.jmedchem.6b00002

Abstact

6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is a member of the folate biosynthesis pathway found in prokaryotes and lower eukaryotes that catalyzes the pyrophosphoryl transfer from the ATP cofactor to a 6-hydroxymethyl-7,8-dihydropterin substrate. We report the chemical synthesis of a series of S-functionalized 8-mercaptoguanine (8MG) analogues as substrate site inhibitors of HPPK and quantify binding against the E. coli and S. aureus enzymes (EcHPPK and SaHPPK). The results demonstrate that analogues incorporating acetophenone-based substituents have comparable affinities for both enzymes. Preferential binding of benzyl-substituted 8MG derivatives to SaHPPK was reconciled when a cryptic pocket unique to SaHPPK was revealed by X-ray crystallography. Differential chemical shift perturbation analysis confirmed this to be a common mode of binding for this series to SaHPPK. One compound (41) displayed binding affinities of 120 nM and 1.76 μM for SaHPPK and EcHPPK, respectively, and represents a lead for the development of more potent and selective inhibitors of SaHPPK.

Legend

Protein

Chemical

Disease

Primary Citation of related structures